St Vincent’s Institute of Medical Research has received a grant of approximately $1 million under the NHMRC 2021 MRFF Cardiovascular Health Mission to fund a major preclinical research project to investigate Cynata’s Cymerus™ mesenchymal stem cells as a treatment for ischemic heart disease.
During Wound Awareness Week (15-21 August), The Adelaide Advertiser spoke with Professor of Regenerative Medicine at UniSA Allison Cowan about Cynata’s Phase 1 diabetic foot ulcer (DFU) clinical trial.
As the temperatures dipped and the southeast coast of Australia shivered through a cold and blustery winter exacerbating joint pain, Dr Ross Macdonald and Professor David Hunter sat down with Rhiannon Down at The Australian to talk about Cynata and the University of Sydney’s osteoarthritis clinical trial.
In July, Cynata received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering the use of its Cymerus™ MSCs in treating asthma and allergic airways disease. The patent adds yet another string to the Company’s bow which now has multiple applications under investigation for its off-the-shelf stem cell product.
A study conducted by Professor Chrishan Samuel, a Monash Biomedicine Discovery Fellow and Head of the Fibrosis Laboratory, Department of Pharmacology at Monash University, found that in an animal model of idiopathic pulmonary fibrosis (IPF), Cynata’s stem cells ameliorated the mediators of lung inflammation while at the same time promoting anti-inflammatory effects. Why is this exciting?